… Oral anticoagulation (OAC) is recommended to reduce the risk of stroke associated with
nonvalvular atrial fibrillation … Warfarin is the most widely prescribed oral anticoagulant in the …

… of oral anticoagulation therapy for real-world atrial fibrillation patients with an elevated risk
of stroke, highlighting the need for improved therapies for stroke prevention in atrial fibrillation. …

… Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet
inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the …

… atrial fibrillation. We included adults with non-valvular atrial fibrillation eligible for oral
anticoagulation… Trials in participants only eligible for parenteral anticoagulation were excluded. …

… of oral anticoagulants vs aspirin (with or without low-dose warfarin) is presented for all 6
outcomes as a hazard ratio. Hazard ratios below 1 indicate that oral anticoagulant decreases …

… the novel oral anticoagulants with the vitamin K antagonists in patients with atrial fibrillation.
We … We found that the novel oral anticoagulants significantly reduced overall mortality, …

… Significant differences in efficacy and safety parameters may exist between oral
anticoagulant agents in patients with atrial fibrillation. Apixaban lowers the risk of major and …

… New oral anticoagulants are a viable option for patients receiving long-term anticoagulation.
Treatment benefits compared with warfarin are small and vary depending on the control …

… New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients …

… of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with
the full … The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation–related …